Modern science has extended beyond merely identifying microbial species and genes to include metabolites, the chemical messengers produced by the gut microbiota. Metabolites permeate the gut barrier, enter the bloodstream, and circulate throughout the body, signalling directly to the brain, immune system, and skin. Consequently, research has demonstrated that gut microbial involvement is not limited to general digestion, but extends to regulating cognition, immunity, skin health, and mental well-being.
Crucially, emerging evidence links age-related microbial decline to diverse diseases across the human lifespan. Scientists have since stressed that shifts in biological needs necessitate targeted supplementation, singling out Human-Residential Bifidobacteria (HRB) as primary species capable of producing health-promoting metabolites at scale.
How Bifidobacteria, especially HRB protect the body
Bifidobacteria are serving as foundational health protectors. Declining bifidobacteria levels, however, compromise this defence system and expose critical vulnerabilities in human physiology. Particularly among adults, research suggests that deficiencies in bifidobacteria are associated with the development of autoimmune diseases, allergies, and metabolic disorders.
Among the numerous species of bifidobacteria, HRB stand out. These unique microbes have coevolved with humans for over 15 million years, providing the body with a plethora of health benefits. Crucially, their production of acetic acid actively safeguards the colon by suppressing harmful bacteria and activating the immune system, thereby bolstering the intestinal barrier. They also serve as a vital food source for butyrate-producing bacteria, while triggering gut hormones like GLP-1 to regulate systemic blood glucose levels. Additionally, HRB leverage genetic tools to process and transform tryptophan into Indole-3-lactic acid (ILA), a powerful antioxidant that bolsters the gut barrier, modulates immunity, and promotes neurological health.
HRB’s mass synthesis of folate represents another cornerstone of its health benefits. Studies show that the human colon can absorb folate. In fact, a recent clinical trial found that approximately 46% of folate delivered to the colon was successfully absorbed. Additionally, colonic folate supports the growth, maintenance, and DNA stability of colonic epithelial cells. Because HRB operate directly in the colon, their production site perfectly matches this target site of action.
From infancy to adulthood
The HRB journey begins during the pre-weaning window of infancy. Once in the gut, HRB leverage a unique tolerance to lysozyme to exclusively consume Human Milk Oligosaccharides (HMOs), complex maternal sugars infants cannot digest alone. Breast milk effectively acts as a natural filtering system, ensuring only these co-evolved microbes establish residence and colonise the infant gut.
Microbiome demands shift with age, evolving from early immune development to maintaining resilience against later stressors like poor diet, stress, and antibiotics. In adulthood, premium HRB species like Bifidobacterium longum protect the gastrointestinal tract; being exclusively adapted to the human host, they colonise the adult gut far better than non-HRB alternatives. These species produce vital metabolites that bolster the intestinal barrier, enhance nutrient absorption, and regulate systemic inflammation to support skin health. This protective shield deteriorates with age, however. Dietary and physiological shifts trigger a sharp decline in HRB, making targeted supplementation critical for health.
Morinaga’s premium probiotic coverage
Bridging these acute vulnerabilities, Morinaga Milk Industry has developed a scientifically backed portfolio of premium HRB probiotics. For early development, Morinaga Milk provides specialised support with B. longum subsp. infantis M-63 and B. breve M-16V.
The M-16V strain reportedly safeguards premature infants from developing necrotising enterocolitis (NEC) and sepsis, while alleviating existing allergic disorders. M-16V also actively promotes gut microbial colonisation and maturation to nurture a healthy gastrointestinal and immune system. Demonstrating its safety and efficacy, the strain has been administered in more than 150 neonatal intensive care units throughout Japan, Australia, New Zealand, and Singapore, under the supervision of doctors.
Complementing these benefits, the M-63 strain possesses a unique capacity to utilise HMOs, which is critical for early infant gut microbiota. Clinical studies note that supplementation of M-63 was associated with improvements in bowel habits and gut environment measures in infants and toddlers during and after the weaning period. The findings also suggest the strain can reduce the number of days with cold-like symptoms for groups at a higher risk of infection.
Later, as biological demands shift toward mature physiological needs, the portfolio introduces B. breve B-3, B. breve MCC1274, and the flagship B. longum subsp. longum BB536 to maintain adult metabolic and immune resilience. The B-3 strain reportedly supports healthy weight management. Clinical data reveal that 12 weeks of B-3 ingestion significantly reduced body fat percentage and mass in pre-obese adults. Ancillary studies demonstrated B-3’s potential to prevent metabolic disorders by suppressing inflammation and improving fat metabolism.
Meanwhile, the multifunctional BB536 works symbiotically with native microbiota to balance gut immunity. Backed by nearly half a century of use across 30 countries, the strain is clinically shown to optimise digestion, balance microflora, regulate immune responses, and protect against infections. Lastly, the gut-brain axis strain, B. breve MCC1274, was clinically demonstrated to maintain memory, significantly improving cognitive function scores in older adults (aged 50–80) with suspected Mild Cognitive Impairment (MCI).
Download the report below to discover how Morinaga Milk Industry’s premium probiotic strains provide targeted supplementation across life stages.
